Karyopharm Therapeutics Inc Stock Price, News & Analysis

Karyopharm Therapeutics (Nasdaq: KPTI) and Menarini Group announced that the UK's Medicines and Healthcare Products Regulatory Agency has granted full Marketing Authorization for NEXPOVIO® (selinexor) in combination with bortezomib and dexamethasone for treating adult patients with multiple myeloma who have had at least one prior therapy. This authorization converts the previous conditional approval to full status, based on results from the Phase 3 BOSTON study that showed significant improvements in disease progression. The Menarini Group will handle commercialization in the UK.

Karyopharm Therapeutics reported total revenue of $157.1 million for 2022, with U.S. XPOVIO® net product revenue of $120.4 million, meeting company guidance. The fourth quarter saw a 4% increase in net product revenue year-over-year. For 2023, the company anticipates total revenue between $160 million and $175 million, including U.S. XPOVIO projections of $125 million to $140 million. Cash reserves are expected to sustain operations until late 2025. The company also revealed advancements in its clinical pipeline, including key studies in myelofibrosis and myelodysplastic neoplasms, with interim data expected in the first half of 2023.

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announced participation in the virtual SVB Securities Global Biopharma Conference on February 16, 2023, at 11:20 a.m. ET. The senior management team will engage in a fireside chat, with a live webcast available for replay on the company's website for 90 days post-event. Karyopharm specializes in novel cancer therapies and is known for its lead compound, XPOVIO® (selinexor), which addresses nuclear export dysregulation in oncogenesis. The company also has a diverse pipeline targeting high unmet cancer needs in multiple myeloma, endometrial cancer, and more. For further details, visit www.karyopharm.com.

Karyopharm Therapeutics Inc. (NASDAQ: KPTI) announced it will release its fourth quarter and full year 2022 financial results on February 15, 2023, during a conference call at 8:00 a.m. ET. The call will cover financial results and company updates. Karyopharm is known for developing novel cancer therapies, including its lead compound, XPOVIO® (selinexor), which is approved in the U.S. for multiple oncology indications. The company is focused on addressing high unmet needs in cancer treatment.

Karyopharm Therapeutics (NASDAQ: KPTI) announced on February 1, 2023, the grant of 113,250 restricted stock units (RSUs) to ten newly hired employees as part of its 2022 Inducement Stock Incentive Plan. The RSUs will vest over three years, with one-third vesting each year, contingent upon the employees' continued service. These grants align with Nasdaq Listing Rule 5635(c)(4), offering incentives to attract talent. Karyopharm develops innovative cancer therapies, including XPOVIO® (selinexor), an oral exportin 1 inhibitor approved for multiple oncology indications in the U.S. and other regions.

Karyopharm Therapeutics announced preliminary unaudited revenue estimates for Q4 and full-year 2022. Total revenue is expected to be approximately $157.7 million, including U.S. XPOVIO net product revenue of $120.4 million, marking a 22% increase from 2021. The company initiated a pivotal Phase 3 study for selinexor in advanced endometrial cancer and plans further studies in myelofibrosis. Additionally, Karyopharm has extended its cash runway to late 2025, emphasizing strong revenue growth and promising clinical pipeline prospects for 2023.

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a leader in cancer therapies, announced its participation in the 41st Annual J.P. Morgan Healthcare Conference. The presentation will occur on January 11, 2023, at 10:30 a.m. PT, followed by a Q&A session at 10:50 a.m. PT. A live webcast will be available on the Company's website and can be replayed for 30 days post-event. Karyopharm is known for its SINE compound technology and its lead product, XPOVIO®, which is approved for various oncology indications. For more details, visit www.karyopharm.com.

Karyopharm Therapeutics (Nasdaq: KPTI) reported promising results from the Phase 1 study of selinexor combined with ruxolitinib for treating treatment-naïve myelofibrosis. At week 24, 92% of efficacy-evaluable patients achieved ≥35% spleen volume reduction (SVR35), while 67% showed ≥50% symptom reduction (TSS50). Additionally, 57% of transfusion-independent patients stabilized their hemoglobin levels. The company aims to advance this combination therapy into randomized trials, highlighting its potential to improve current treatment standards.

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announced a webcast on December 12, 2022, to present updated Phase 1 study results on selinexor combined with ruxolitinib for treating treatment-naïve myelofibrosis. Key opinion leaders, including Dr. Haris Ali and Dr. Srdan Verstovsek, will discuss data and the treatment landscape. The webcast will be accessible on the company's investor website. Karyopharm also has multiple presentations scheduled at the ASH 2022 Annual Meeting, focusing on its cancer therapies, particularly XPOVIO, which has various regulatory approvals worldwide.